Jimenez-Labaig, Pablo;
Rullan, Antonio;
Hernando-Calvo, Alberto;
Llop, Sandra;
Bhide, Shreerang;
O'Leary, Ben;
Brana, Irene;
(2024)
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Cancer Treatment Reviews
, 128
, Article 102772. 10.1016/j.ctrv.2024.102772.
![[thumbnail of Rullan_ADC BsAb HNSCC and NPC_Reviewed_ Clean.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Rullan_ADC BsAb HNSCC and NPC_Reviewed_ Clean.pdf - Accepted Version Access restricted to UCL open access staff until 1 June 2025. Download (825kB) |
Abstract
Introduction: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. Antibody-drug conjugates (ADC) and bispecific antibodies (BsAb) may deliver promising results. Methods: We conducted a systematic literature review to identify ADC and BsAb clinical trials, involving patients with HNSCC and NPC, from database creation to December 2023. We reported trial characteristics, overall response rate (ORR), overall survival (OS), and grade ≥ 3 treatment-related adverse events (trAEs). Results: 23 trials (65 % phase I) were found, involving 540 R/M patients (355 [20trials] HNSCC and 185 [5trials] NPC). There were 13 ADC (n = 343) and 10 BsAb (n = 197) trials. 96 % patients were refractory to standard of care treatments. ORR ranged from 0 to 100 %, with the highest ORR for GEN1042 plus chemoimmunotherapy. ORRs for monotherapies were 47 % for ADC, and 0–37 % for BsAb. MRG003 reached in HNSCC 43 % and NPC 47 %. BL-B01D1 54 % in NPC. Longest median OS was seen with MRG003 and KN046. Grade ≥ 3 trAEs were 28–60 % in ADC trials, and 3–33 % BsAb. Grade ≥ 3 myelosuppressive trAEs were typically seen in 8 ADC trials, while 4 BsAb showed infusion-related reactions (IRR). Four treatment-related deaths were reported (1 pneumonitis), all ADC trials. Conclusion: ADC and BsAb antibodies show promise in R/M HNSCC and NPC. Results are premature by small sample sizes and lack of control arm. ADC mainly caused myelosuppression and a pneumonitis case, and BsAb IRR. Further research is warranted in this setting.
| Type: | Article |
|---|---|
| Title: | A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies |
| Location: | Netherlands |
| DOI: | 10.1016/j.ctrv.2024.102772 |
| Publisher version: | http://dx.doi.org/10.1016/j.ctrv.2024.102772 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | 1ST-LINE TREATMENT, ADC, Antibody -drug conjugate, Bispecific antibody, CETUXIMAB, CRITERIA, GUIDELINES, HNSCC, Life Sciences & Biomedicine, MULTICENTER, Nasopharyngeal carcinoma, Oncology, OPEN-LABEL, PEMBROLIZUMAB, PLUS CHEMOTHERAPY, RECURRENT, Science & Technology, Squamous cell carcinoma, TRASTUZUMAB EMTANSINE |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10197976 |
Archive Staff Only
 |
View Item |
